title: Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
abstract: Neoadjuvant chemotherapy is the standard of care for patients with large, inoperable tumors or inflammatory breast cancer, but it is also increasingly considered for women with operable disease. Several randomized trials have demonstrated that anthracycline- and taxane-containing regimens in operable breast cancer were equally effective in terms of disease-free or overall survival regardless of whether they were administered postoperatively or preoperatively. Further neoadjuvant treatment allows for a higher rate of breast conserving surgery. Tumor responses in terms of pathologic complete remission after short-term chemotherapy will probably only serve as a surrogate marker for long-term outcome in some molecular breast cancer subtypes like the triple-negative, HER2-positive, and some luminal B subsets. Recent trials showed that in HER2-positive disease pCR rates were as high as 70% when 2 HER2-targeted agents were added to chemotherapy.
authors.affiliation: Breast Center, Kantonsspital St. Gallen, Switzerland.
authors.forename: Jens
authors.initials: J
authors.lastname: Huober
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz